MedTrace Logo

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

NCT05521802 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2023-03-24

No results posted yet for this study

Summary

This is a multicenter, open-label study to evaluate the safety and efficacy of C-CAR088 in patients with relapsed or refractory multiple myeloma. The phase Ib part of this study is to determine the recommended phase 2 dose (RP2D) of C-CAR088 in the targeted patient population.

Conditions

Interventions

BIOLOGICAL

B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell

Autologous 2nd generation BCMA-directed CAR-T cells, single infusion intravenously

Sponsors & Collaborators

  • Shanghai AbelZeta Ltd.

    lead INDUSTRY

Principal Investigators

  • Lugui Qiu · Institute of Hematology & Blood Diseases Hospital, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-11
Primary Completion
2024-07-31
Completion
2037-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05521802 on ClinicalTrials.gov